MDS (myelodysplastic syndromes) is a heterogeneous group of
malignant hematopoietic stem cell disorders that are characterized by
dysplastic and ineffective blood cell production with a variable risk of
transformation to acute leukemia. Explaining MDS to patients and their
families can be difficult for healthcare professionals (HCPs). The disease
process is complex, the prognosis variable, and treatment options must be
tailored for each individual patient.
Often the information gap between what HCPs believe they are
communicating to their patients and what patients comprehend can be immense.
Thus it is imperative that patient-HCP communications are effective to ensure
optimal outcomes when managing patients with MDS
Faculty
Christopher R. Cogle, MD
Associate Professor, College of Medicine, Department of
Medicine, Division of Hematology/Oncology
University of Florida Blood & Marrow Transplant Program
Leslie C. Pettiford, RN, BSN, CCRC
Registered Nurse Specialist, Clinical Research Coordinator
University of Florida Health Cancer Center